Recombinant proteins secreted from tissue-engineered bioartificial muscle improve cardiac dysfunction and suppress cardiomyocyte apoptosis in rats with heart failure

Chinese Medical Journal

Volumn 123, Issue 24, 2010, Pages 3626-3633

  Rong, Shu Ling ^a   Wang, Yong Jin ^a   Wang, Xiao Lin ^a   Lu, Yong Xin ^b   Wu, Yin ^c   Liu, Qi Yun ^b   Mi, Shao Hua ^b   Xu, Yu Lan ^b  

^a CHANGZHI MEDICAL COLLEGE   (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c SOUTH CHINA NORMAL UNIVERSITY   (China)

Author keywords

Gene therapy; Heart failure; Insulin like growth factor 1; Muscles

Indexed keywords

CASPASE 3; GREEN FLUORESCENT PROTEIN; MESSENGER RNA; PROTEIN BAX; PROTEIN BCL 2; RECOMBINANT SOMATOMEDIN C; RETROVIRUS VECTOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; BIOARTIFICIAL ORGAN; CONTROLLED STUDY; DOWN REGULATION; EX VIVO GENE TRANSFER; GENE EXPRESSION REGULATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PROTEIN LOCALIZATION; RADIOIMMUNOASSAY; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TISSUE ENGINEERING; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CASPASE 3; DESMIN; GENE THERAPY; HEART FAILURE; INSULIN-LIKE GROWTH FACTOR I; MYOBLASTS, SKELETAL; MYOCYTES, CARDIAC; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RETROVIRIDAE; TISSUE ENGINEERING; TUMOR NECROSIS FACTOR-ALPHA; VENTRICULAR FUNCTION, LEFT;

EID: 78650612238     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2010.24.022     Document Type: Article

References (30)

1. Premaratne GU, Tambara K, Fujita M, Lin X, Kanemitsu N, Tomita S, et al. Repeated implantation is a more effective cell delivery method in skeletal myoblast transplantation for rat myocardial infarction. Circ J 2006; 70: 1184-1189.
2. Dib N, Michler RE, Pagani FD, Wright S, Kereiakes DJ, Lengerich R, et al. Safety and feasibility of autologous myoblast transplantation in patients with ischemic cardiomyopathy four-year follow-up. Circulation 2005; 112: 1748-1755.
3. McElhinney DB, Colan SD, Moran AM, Wypij D, Lin M, Majzoub JA, et al. Recombinant human growth hormone treatment for dilated cardiomyopathy in children. Pediatrics 2004; 114: e452-e458.
4. Russell-Jones DL, Bates AT, Umpleby AM, Hennessy TR, Bowes SB, Hopkins KD, et al. A comparison of the Effects of IGF-1 and insulin on glucose metabolism, fat metabolism and the cardiovascular system innormal human volunteers. Eur J Clin Invest 1995; 25: 403-411.
5. Donath MY, Jenni R, Brunner HP, Anrig M, Kohli S, Glatz Y, et al. Cardiovascular and metabolic effects of insulin like growth factor at rest and during exercise in humans. J Clin Endocrinol Metab 1996; 81: 4089-4094.
6. Vandenburgh H, Del Tatto M, shansky J, Goldstein L, Russell LK, Genes N, et al. Attenuation of skeletal muscle wasting with recombinant human growth hormone secreted from a tissue-engineered bioartificial muscle. Hum Gene Ther 1998; 9: 2555-2564.
7. Mohamed-Ali V, Pinkney J. Therapeutic potential of insulin-like growth factor-1 in patients with diabetes mellitus. Treat Endocrinol 2002; 1: 399-410.
8. Schertzer JD, Lynch GS. Comparative evaluation of IGF-I gene transfer and IGF-I protein administration for enhancing skeletal muscle regeneration after injury. Gene Ther 2006; 13: 1657-1664.
9. Liu TB, Fedak PW, Weisel RD, Yasuda T, Kiani G, Mickle DA, et al. Enhanced IGF-1 expression improves smooth muscle cell engraftment after cell transplantation. Am J Physiol Heart Circ Physiol 2004; 287: H2840-H2849.
10. Su EJ, Cioffi CL, Stefansson S, Mittereder N, Garay M, Hreniuk D, et al. Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularization. Am J Physiol Heart Circ Physiol 2003; 284: H1429-H1440.
11. Ylä-Herttuala S, Alitalo K. Gene transfer as a tool to induce therapeutic vascular growth. Nat Med 2003; 9: 694-701.
12. Gounis MJ, Spiga MG, Graham RM, Wilson A, Haliko S, Lieber BB, et al. Angiogenesis is confined to the transient period of VEGF expression that follows adenoviral gene delivery to ischemic muscle. Gene Ther 2005; 12: 762-771.
13. Rong SL, Lu YX, Liao YH, Wang XL, Guo HP, Chang C, et al. Effects of recombinant retroviral vector mediated human insulin like growth factor-1 gene transfection on skeletal muscle growth in rat. Chin Med J 2006; 119: 1991-1998.
14. Shansky J, Del Tatto M, Chromiak J, Vandenburgh HH. A simplified method for tissue engineering skeletal muscle organoids in vitro. In Vitro Cell Dev Biol Anim 1997; 33: 659-661.
15. Rong SL, Wang YJ, Wang XL, Lu YX, Chang C, Wang FZ, et al. Recombinant human growth hormone secreted from tissue-engineered bioartificial muscle improves left ventricular function in rat with acute myocardial infarction. Chin Med J 2009; 122: 2352-2359.
16. Rong SL, Lu YX, Liao YH, Wang Xl, Wang YJ, Chang C, et al. Effetcs of transplantated myoblasts transfected with human growth hormone gene on improvement of Ventricular function of rats. Chin Med J 2008; 121: 347-354.
17. Ly H, Kawase Y, Yoneyama R, Hajjar RJ. Gene therapy in the treatment of heart failure. Physiology 2007; 22: 81-96.
18. Vinge LE, Raake PW, Koch WJ. Gene therapy in heart failure. Circ Res 2008; 102: 1458-1470.
19. Adriaansen J, Vervoordeldonk MJ, Tak PP. Gene therapy as a therapeutic approach for the treatment of rheumatoid arthritis: innovative vectors and therapeutic genes. Rheumatology 2006: 45: 656-668.
20. Lu Y, Shansdy J, Del Tatto M, Ferland P, Wang X, Vandenburgh H. Ricombinant vascular endothelial growth factor secreted from tissue-engineered bioartificial muscles promotes localized angiogenesis. Circulation 2001; 1004: 594-599.
21. Lu Y, Shansky J, Del Tatto M, Ferland P, McGuire S, Marszalkowski J, et al. Therapeutic potential of implanted tissue-engineered bioartificial musclis delivering recombinant proteins to the sheep heart. Ann N Y Acad Sci 2002; 961: 78-82.
22. Thorrez L, Vandenburgh H, Callewaert N, Mertens N, Shansky J, Wang L, et al. Angiogenesis enhances factor IX delivery and persistence from retrievable human bioengineered muscle implants. Mol Ther 2006; 14: 442-451.
23. Takahashi T, Song Q, Zhang S, Kamm RD, Grodzinsky AJ, Anversa P, et al. Local myocardial insulin-like growth factor 1 (IGF-1) delivery with biotinylated peptide nanofibers improves cell therapy for myocardial infarction. Proc Natl Acad Sci U S A 2006; 103: 8155-8160.
24. Welch S, Plank D, Witt S, Glascock B, Schaefer E, Chimenti S, et al. Cardiac-specific IGF-1 expression attenuates dilated cardiomyopathy in tropomodulin-overexpressing transgenic mice. Circ Res 2002; 90: 641-648.
25. Tokunou T, Miller R, Patwari P, Davis ME, Segers VF, Grodzinsky AJ, et al. Engineering insulin-like growth factor-1 for local delivery. FASEB J 2008; 22: 1886-1893.
26. Gargosky S, Tapanainen P, Rosenfeld R. Administration of growth hormone (GH) but not insulin-like factor-1 (IGF-1), by continuous infusion can induce the formation of the 150-kilodalton IGF-binding protein-3 complex in GH-deficient rats. Endocrinology 1994; 134: 2267-2276.
27. Guo XM, Wang HL, Chu HY, Wang X, Qu B, Li Z, et al. High level expression of human factor VIII in mammalian cells after retroviral-mediated gene transfer. Chin Med J 2001; 114: 690-693.
28. Dolnikov A, Wotherspoon S, Millington M, Symonds G. Retrovirus vector production and transduction: modulation by the cell cycle. Gen Virol 2003; 84: 3131-3141.
29. Habu Y, Miyano-Kurosaki N, Kitano M, Endo Y, Yukita M, Ohira S, et al. Inhibition of HIV-1 gene expression by retroviral vector-mediated small-guide RNAs that direct specific RNA cleavage by tRNase ZL. Nucleic Acids Res 2005; 33: 235-243.
30. Powell C, Shansky J, Del Tatto M, Forman DE, Hennessey J, Sullivan K, et al. Tissue-engineered human bioartificial muscles expressing a foreign recombinant protein for gene therapy. Hum Gene Ther 1999; 10: 565-577.